Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia. Issue 11 (November 2014)

• Record Type: Journal Article
• Authors: Malhotra, Hemant; Sharma, Pratibha; Bhargava, Shipra; Rathore, Om Singh; Malhotra, Bharti; Kumar, Madhu
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 11(2014:Nov.)
• Page Start: 2614
• Page End: 2619
• Publication Date: 2014-11
• Subjects: Chronic myeloid leukemia (CML) -- imatinib -- major molecular response (MMR) -- real time polymerase chain reaction (RQ-PCR) -- receiver operating characteristic (ROC) curve; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.885515
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The present study looked at the correlation between mean trough Imatinib plasma levels and molecular response in 131 CML patients on imatinib. Patients receiving Glivec versus generic Imatinib were also compared. A ROC curve was constructed to estimate a threshold level that correlates with a favourable response. Patients were grouped into Responders (bcr/abl ration by RQ-PCR less than 1) and Non Responders (ration ≥ 1). The mean trough imatinib plasma level in the responders was significantly higher than in the non responders (p = 0.001). The area under ROC curve was 0.733, with best sensitivity (51.85%) and specificity (89.42%) at a plasma threshold of 0.988 g/ml [1.675 M]. Levels in the patients on Glivec versus generic drug (p > 0.05) were comparable. Trough Imatinib plasma levels may be a marker for suboptimal response and may identify patients in whom increase of drug dose or change in therapy may be indicated.